All In Biotech

Drug Trial Radar · NCT05946876

A Phase 1 Study of XH-S003 in Healthy Volunteers

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics of XH-S003 After Single and Multiple Ascending Doses, Plus the Evaluation of Food Effects in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

77

Actual

Start

Aug 24, 2023

Primary completion

Jul 11, 2024

Study completion Aug 14, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 1, randomised, first-in-human, double-blinded, placebo-controlled, SAD (Single Ascending Dose) and MAD (Multiple Ascending Dose) study to assess the PK, safety, and tolerability of XH-S003 in healthy volunteers. In addition, this study evaluates the effects of food on XH-S003 under a two-period, cross-over study setting.

Conditions

  • Healthy

Interventions

  • XH-S003 (A)Drug

    IP: XH-S003 IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

  • Placebo (B)Other

    Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Part A: Upto 10 days
  2. Number of participants with adverse events (AEs)Time frame: Part B: Up to 28 days
  3. Number of participants with adverse events (AEs)Time frame: Part C: Up to 7 days
  4. Number of participants with clinical laboratory abnormalitiesTime frame: Part A: Upto 10 days
  5. Number of participants with clinical laboratory abnormalitiesTime frame: Part B: Up to 28 days
  6. Number of participants with clinical laboratory abnormalitiesTime frame: Part C: Up to 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.